OurCrowd portfolio company ElMindA was featured in The Times of Israel, an English-language news website covering Israel, the region & the Jewish world. ElMindA is the world’s first FDA-cleared neuronal functional assessment tool. ElMindA’s solution uniquely measures how different parts of the brain communicate by uploading measured neural activity into the cloud where proprietary algorithms map out neural association.
Fresh from its recent award as one of the 49 most innovative startups in the world by the World Economic Forum, Israeli biotechnology firm ElMindA, developers of the world’s first FDA-approved neural functional assessment tool to visualize serious brain trauma and illnesses, announced last week that it had received $28 million in a Series C financing round.
ElMindA had to turn away investors anxious to put their money into what could be the next big Israeli med tech exit, according to investment experts familiar with the firm.
ElMindA raised $2,282,318 from OurCrowd investors in July 2015.
Read more on The Times of Israel here.
